- List
- By Topic
- On Map
- Search Details

"WHIMS" (44 records)
Need help? See Downloading Content for Analysis
For Advanced Users: Full Study Record XML Download
1 | NCT03087370 | Not yet recruiting | A Retrospective and Prospective Natural History Study of Patients With WHIM Syndrome |
|
|
Observational |
|
Industry |
|
|
100 | All | Child, Adult, Senior | NCT03087370 | X4-WHIM-NTHX | March 2017 | March 2022 | March 2022 | March 22, 2017 | March 28, 2017 | ||||
2 | NCT03005327 | Recruiting | A Trial of X4P-001 in Patients With WHIM Syndrome |
|
|
Interventional | Phase 2 Phase 3 |
|
Industry |
|
|
42 | All | 13 Years and older (Child, Adult, Senior) | NCT03005327 | X4P-001-MKKA | X4P-001-MKKA | December 2016 | May 2019 | August 2019 | December 29, 2016 | January 10, 2018 |
|
|
3 | NCT00967785 | Recruiting | A Phase I Study of Mozobil in the Treatment of Patients With WHIMS |
|
|
Interventional | Phase 1 |
|
NIH |
|
|
20 | All | 18 Years to 75 Years (Adult, Senior) | NCT00967785 | 090200 09-I-0200 |
August 4, 2009 | June 1, 2019 | December 31, 2019 | August 28, 2009 | March 29, 2018 |
|
||
4 | NCT02231879 | Recruiting | Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome |
|
|
Interventional | Phase 3 |
|
NIH |
|
|
30 | All | 10 Years to 75 Years (Child, Adult, Senior) | NCT02231879 | 140185 14-I-0185 |
September 3, 2014 | September 30, 2020 | March 31, 2021 | September 4, 2014 | March 29, 2018 |
|
||
5 | NCT00739869 | Completed | Evaluating the Effects of Hormone Replacement Therapy on Brain Function (The WHIMS-MRI Study) |
|
Observational |
|
NIH / Other |
|
|
1426 | Female | 65 Years and older (Adult, Senior) | NCT00739869 | 571 N01-WH-4-4221 |
WHIMS-MRI | May 2004 | April 2006 | March 2007 | August 22, 2008 | October 19, 2015 |
|
|||
6 | NCT01905475 | Completed | CXCR4 Antagonism for Cell Mobilisation and Healing in Acute Myocardial Infarction (CATCH-AMI) |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
120 | All | 18 Years to 80 Years (Adult, Senior) | NCT01905475 | POL6326-POL-006 | CATCH-AMI | July 2013 | October 2015 | June 2016 | July 23, 2013 | June 10, 2016 |
|
|
7 | NCT02115672 | Withdrawn | Imatinib and BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leukemia |
|
|
Interventional | Phase 1 Phase 2 |
|
Other |
|
|
0 | All | 18 Years to 70 Years (Adult, Senior) | NCT02115672 | SHEBA-13-0575-AN-CTIL | November 2014 | November 2016 | November 2018 | April 16, 2014 | August 15, 2016 |
|
||
8 | NCT02069080 | Suspended | Imaging CXCR4 Expression in Subjects With Cancer Using 64 Cu-Plerixafor |
|
|
Interventional | Early Phase 1 |
|
NIH / Other |
|
|
2 | All | 18 Years to 99 Years (Adult, Senior) | NCT02069080 | 140050 14-I-0050 |
February 20, 2014 | October 31, 2018 | October 31, 2018 | February 21, 2014 | March 29, 2018 |
|
||
9 | NCT01010880 | Completed | Safety Study of a Chemokine Receptor (CXCR4) Antagonist in Multiple Myeloma Patients |
|
|
Interventional | Phase 1 Phase 2 |
|
Industry |
|
|
16 | All | 16 Years to 65 Years (Child, Adult) | NCT01010880 | BKTSC001 | October 2008 | July 2010 | July 2010 | November 10, 2009 | June 10, 2011 |
|
||
10 | NCT03436342 | Not yet recruiting | Chemokine Receptor CXCR4-targeting Molecular Imaging for Metabolic Characterization of Multiple Myeloma and Lymphoma |
|
|
Interventional | Early Phase 1 |
|
Other |
|
|
100 | All | 18 Years and older (Adult, Senior) | NCT03436342 | PekingUMCHCXCR4 | May 1, 2018 | March 1, 2020 | December 1, 2020 | February 16, 2018 | March 20, 2018 |
|
||
11 | NCT03020524 | Recruiting | Autologous CD4 T-Cells in HIV (C34-CXCR4) |
|
|
Interventional | Early Phase 1 |
|
Other |
|
|
9 | All | 18 Years and older (Adult, Senior) | NCT03020524 | 826035 | January 2017 | January 2018 | June 2018 | January 13, 2017 | February 8, 2018 |
|
||
12 | NCT03225716 | Recruiting | A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia |
|
|
Interventional | Phase 1 Phase 2 |
|
Other / Industry |
|
|
38 | All | 18 Years and older (Adult, Senior) | NCT03225716 | 17-235 | October 20, 2017 | January 31, 2021 | January 31, 2025 | July 21, 2017 | April 6, 2018 |
|
||
13 | NCT00685009 | Completed | The Women's Health Initiative Memory Study (The WHIMS Study) |
|
|
Observational |
|
NIH / Other |
|
|
7525 | Female | 65 Years to 79 Years (Adult, Senior) | NCT00685009 | 548 N01-WH44221 |
January 1996 | September 1997 | March 2008 | May 28, 2008 | October 19, 2015 |
|
|||
14 | NCT01236144 | Completed | A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome. |
|
|
Interventional | Phase 1 Phase 2 |
|
Other |
|
|
113 | All | 60 Years and older (Adult, Senior) | NCT01236144 | SPON 845-10 2010-021444-18 10/MRE09/27 |
AML18 Pilot | April 2011 | December 2013 | January 2014 | November 8, 2010 | June 11, 2014 |
|
|
15 | NCT01295242 | Completed | Natural History of Human Papillomavirus (HPV) Infections in Mid-Adult Women (WHIM) |
|
Observational |
|
Other |
|
|
409 | Female | 30 Years to 50 Years (Adult) | NCT01295242 | 39810-C | WHIM | February 2011 | August 2012 | August 2012 | February 14, 2011 | November 19, 2013 |
|
|||
16 | NCT00745056 | Active, not recruiting | Examining the Relationship Between Hormone Therapy (HT) and Cognitive Function (The WHIMS-ECHO Study) |
|
Observational |
|
Other |
|
|
2922 | Female | 65 Years and older (Adult, Senior) | NCT00745056 | 1436 | WHIMS-ECHO | August 2008 | November 2021 | November 2021 | September 1, 2008 | November 6, 2017 |
|
|||
17 | NCT00173849 | Unknown † | The Role of SDF-1/CXCR4 in Metastasis of Oral Squamous Cell Carcinoma |
|
Observational |
|
Other |
|
100 | All | 30 Years to 75 Years (Adult, Senior) | NCT00173849 | 9461700656 | January 2006 | July 2006 | September 15, 2005 | September 15, 2005 |
|
||||||
18 | NCT01072734 | Completed | Auto-immunity in Lupus Patients After Influenza Vaccine |
|
|
Interventional | Phase 2 |
|
Other |
|
|
28 | All | 18 Years and older (Adult, Senior) | NCT01072734 | P090104 | GRIPLUP | September 2009 | January 2010 | February 2010 | February 22, 2010 | October 13, 2010 |
|
|
19 | NCT01686685 | Completed | Correlation of CXCR4 Expression in Premature Infants With a Diagnosis of Autism at 24 Months |
|
Observational |
|
Other |
|
|
400 | All | up to 1 Day (Child) | NCT01686685 | begin1HMO-CTIL | ASD-CXCR4 | September 2013 | April 2018 | April 1, 2018 | September 18, 2012 | April 12, 2018 |
|
|||
20 | NCT00174096 | Unknown † | The Role of Stromal Cell-Derived Factor-1 (SDF-1)/CXC Chemokine Receptor 4 (CXCR4) in Metastasis of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma |
|
Observational |
|
Other |
|
100 | All | 30 Years to 75 Years (Adult, Senior) | NCT00174096 | 9461700624 | August 2005 | July 2006 | September 15, 2005 | March 31, 2006 |
|
||||||
21 | NCT00089466 | Completed | Safety and Activity of the Oral HIV Entry Inhibitor AMD11070 in HIV Infected Patients |
|
|
Interventional | Phase 1 Phase 2 |
|
NIH / Other |
|
|
6 | All | 18 Years and older (Adult, Senior) | NCT00089466 | A5210 10020 ACTG A5210 |
November 2004 | June 2006 | January 2009 | August 6, 2004 | October 31, 2012 |
|
||
22 | NCT01058993 | Completed Has Results |
AMD 3100 for Treatment of Myelokathexis |
|
|
Interventional | Phase 1 |
|
Other |
|
|
6 | All | 18 Years and older (Adult, Senior) | NCT01058993 | 35419-D MAMO-0407-1 |
October 2010 | March 2011 | April 2011 | January 29, 2010 | June 15, 2012 | June 15, 2012 |
|
|
23 | NCT01374503 | Terminated | First in Man Study of ALX-0651, a Nanobody Inhibiting CXCR4 |
|
|
Interventional | Phase 1 |
|
Industry |
|
|
52 | Male | 18 Years to 55 Years (Adult) | NCT01374503 | ALX-0651-1.1/11 | June 2011 | January 2012 | January 2012 | June 16, 2011 | April 17, 2012 |
|
||
24 | NCT01359657 | Completed | Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma |
|
|
Interventional | Phase 1 |
|
Industry |
|
|
46 | All | 18 Years and older (Adult, Senior) | NCT01359657 | CA212-002 | September 2011 | March 2016 | March 2016 | May 25, 2011 | March 16, 2016 |
|
||
25 | NCT00155844 | Unknown † | Studies on the Significance of CXCR4-CXCL12 on Leukemic Cells Passing Through"Marrow-Blood Barrier" |
|
Observational |
|
Other |
|
30 | All | Child, Adult, Senior | NCT00155844 | 9200200606 | February 2003 | July 2004 | September 12, 2005 | September 12, 2005 |
|
||||||
26 | NCT01120457 | Completed | First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers |
|
|
Interventional | Phase 1 |
|
Industry |
|
|
96 | All | 18 Years and older (Adult, Senior) | NCT01120457 | CA212-001 | August 2010 | November 2014 | November 2014 | May 11, 2010 | March 6, 2015 |
|
||
27 | NCT02605460 | Recruiting | Chemo Sensitization Before Hematopoietic Stem Cell Transplantation in Patients With Acute Leukemia in Complete Remission |
|
|
Interventional | Phase 2 |
|
Other |
|
|
20 | All | 18 Years to 60 Years (Adult) | NCT02605460 | INCMNSZ REF 917 | February 2014 | June 2018 | December 2018 | November 16, 2015 | November 13, 2017 |
|
||
28 | NCT01272674 | Completed | Adiponectin and Circulating Progenitor Cells (CPC) Function |
|
|
Interventional | Phase 1 |
|
Other |
|
|
20 | Male | 18 Years to 75 Years (Adult, Senior) | NCT01272674 | adipo2008 | January 2011 | March 2011 | March 2011 | January 10, 2011 | June 2, 2015 |
|
||
29 | NCT02737072 | Terminated | A Study of LY2510924 and Durvalumab in Participants With Solid Tumors |
|
|
Interventional | Phase 1 |
|
Industry |
|
|
45 | All | 18 Years and older (Adult, Senior) | NCT02737072 | 16387 I2V-MC-CXAD |
September 2016 | September 2017 | September 2017 | April 13, 2016 | November 17, 2017 | |||
30 | NCT00321438 | Terminated | Observational Study of HIV-Infected Subjects With X4-Tropic or Non-Phenotypeable Virus |
|
Observational |
|
Industry |
|
150 | All | 18 Years and older (Adult, Senior) | NCT00321438 | CCR104629 | July 2005 | May 3, 2006 | May 18, 2009 |
|
|||||||
31 | NCT03277209 | Recruiting | To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on the Immune Microenvironment in Patients With Pancreatic, Ovarian and Colorectal Adenocarcinomas |
|
|
Interventional | Phase 1 |
|
Other |
|
|
28 | All | 18 Years and older (Adult, Senior) | NCT03277209 | 1508016466 | July 25, 2017 | December 2019 | December 2020 | September 8, 2017 | September 8, 2017 |
|
||
32 | NCT02179970 | Recruiting | To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovarian and Colorectal Cancers |
|
|
Interventional | Phase 1 |
|
Other / Industry |
|
|
28 | All | 16 Years and older (Child, Adult, Senior) | NCT02179970 | CAM-PLEX 2014-000117-31 |
CAM-PLEX | June 2015 | March 2018 | June 2018 | July 2, 2014 | January 9, 2018 |
|
|
33 | NCT00512252 | Completed Has Results |
AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia |
|
|
Interventional | Phase 1 Phase 2 |
|
Other |
|
|
52 | All | 18 Years to 70 Years (Adult, Senior) | NCT00512252 | 07-0227 / 201011796 | AMD3100+MEC | July 2007 | June 2010 | June 2010 | August 7, 2007 | December 12, 2016 | September 22, 2014 |
|
34 | NCT00063804 | Completed | Safety of AMD070 When Administered Alone or Boosted With Low-Dose Ritonavir in HIV Uninfected Men |
|
|
Interventional | Phase 1 |
|
NIH / Other |
|
|
44 | Male | 18 Years to 55 Years (Adult) | NCT00063804 | A5191 10012 ACTG A5191 |
October 2006 | July 8, 2003 | May 21, 2012 |
|
||||
35 | NCT03335670 | Recruiting | Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors |
|
|
Interventional | Early Phase 1 |
|
Other / NIH |
|
|
30 | All | 18 Years and older (Adult, Senior) | NCT03335670 | 201708705 P50CA174521 |
November 3, 2017 | October 1, 2019 | December 31, 2020 | November 8, 2017 | January 9, 2018 |
|
||
36 | NCT01841476 | Completed | Safety and Efficacy of POL6326 for Mobilization of Hematopoietic Stem Cells in Healthy Volunteers |
|
|
Interventional | Phase 1 |
|
Industry |
|
|
27 | Male | 18 Years to 55 Years (Adult) | NCT01841476 | POL-3 | February 2012 | August 2015 | September 2015 | April 26, 2013 | November 25, 2015 |
|
||
37 | NCT00906945 | Completed Has Results |
Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia |
|
|
Interventional | Phase 1 Phase 2 |
|
Other |
|
|
39 | All | 18 Years to 70 Years (Adult, Senior) | NCT00906945 | 10-0910 / 201106039 | February 2011 | November 2012 | September 2015 | May 21, 2009 | April 4, 2017 | April 4, 2017 |
|
|
38 | NCT00733824 | Completed Has Results |
Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphoma |
|
|
Interventional | Phase 1 Phase 2 |
|
Other |
|
|
61 | All | 18 Years to 75 Years (Adult, Senior) | NCT00733824 | 08-0897 / 201105349 | November 2008 | September 2012 | September 2013 | August 13, 2008 | March 9, 2017 | October 28, 2016 |
|
|
39 | NCT00322127 | Completed | An Evaluation of Safety and Efficacy of Escalating Doses of AMD3100 to Mobilize CD34+ Cells in Healthy Volunteers |
|
|
Interventional | Phase 1 |
|
NIH |
|
|
44 | All | 18 Years to 50 Years (Adult) | NCT00322127 | 060156 06-H-0156 |
May 3, 2006 | January 23, 2015 | January 23, 2015 | May 5, 2006 | March 29, 2018 |
|
||
40 | NCT00302562 | Unknown † | The Role of MMPs in the CXCL12-Induced Invasion of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma |
|
Observational |
|
Other |
|
100 | All | 30 Years to 75 Years (Adult, Senior) | NCT00302562 | 9461701234 | August 2006 | July 2007 | March 14, 2006 | March 14, 2006 |
|
||||||
41 | NCT02765165 | Active, not recruiting | Phase 1/2 Study of USL311 Alone and in Combination With Lomustine in Subjects With Advanced Solid Tumors and Relapsed/Recurrent Glioblastoma Multiforme (GBM) |
|
|
Interventional | Phase 1 Phase 2 |
|
Industry |
|
|
120 | All | 18 Years and older (Adult, Senior) | NCT02765165 | P311-201 | April 2016 | December 2019 | May 6, 2016 | September 12, 2017 |
|
|||
42 | NCT00299897 | Unknown † | SP01A: The Study of an Oral Entry Inhibitor in Treatment-Experienced HIV Patients |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
60 | All | 18 Years to 60 Years (Adult) | NCT00299897 | SP01A-111-05 | March 2006 | March 7, 2006 | October 27, 2006 |
|
||||
43 | NCT00082329 | Completed Has Results |
G-CSF and AMD3100 to Mobilize Stem Cells in Healthy Volunteers |
|
|
Interventional | Phase 2 |
|
NIH |
|
|
9 | All | 18 Years to 60 Years (Adult) | NCT00082329 | 040179 04-H-0179 |
May 2004 | October 2012 | October 2012 | May 6, 2004 | May 2, 2014 | May 2, 2014 |
|
|
44 | NCT00243568 | Terminated | Vicriviroc, a CCR5 Inhibitor, Added to an Optimized Antiretroviral Therapy for Previously Treated HIV (VICTOR-E2) (Study P04285)(TERMINATED) |
|
|
Interventional | Phase 3 |
|
Industry |
|
500 | All | 18 Years and older (Adult, Senior) | NCT00243568 | P04285 EudraCT number 2005-001058-26 |
September 2005 | October 24, 2005 | October 23, 2009 |
† Study has passed its completion date and status has not been verified in more than two years.